WAP
AYTU icon

Wealthcare Advisory Partners’s AYTU BioPharma AYTU Stock Holding History

Wealthcare Advisory Partners’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20
Closed -$6K – 398
2020
Q1 		$6K Buy
+20
New +$3.86K ﹤0.01% 1037

Other funds holding AYTU

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Wealthcare Advisory Partners's AYTU Position: Q2 2020 in Review

Wealthcare Advisory Partners sold out of AYTU BioPharma (AYTU) in Q2 2020, closing a stake of 20 shares — an estimated $6K sold.

Wealthcare Advisory Partners first reported a position in AYTU in Q1 2020 and held it in 1 quarter. The position peaked at $6K in Q1 2020. 66 funds tracked by Wall St. Rank hold AYTU as of Q2 2020.

  • Wealthcare Advisory Partners reported no remaining AYTU BioPharma position as of Q2 2020 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 20 AYTU BioPharma shares in Q2 2020, an estimated $6K.
  • Wealthcare Advisory Partners first reported a position in AYTU BioPharma in Q1 2020 and held it in 1 quarter.
  • Wealthcare Advisory Partners's AYTU BioPharma position peaked at $6K in Q1 2020.
  • 66 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2020.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2020, filed 29 Jul 2020.